Table 2.

Clinical trials using pRB status as a biomarker.

Tumor	Interventions	Significance of pRB status	Study phase	Trial
Breast, prostate, pancreatic, glioma, gastrointestinal stromal tumors	Abemaciclib, palbociclib, ribociclib	Inclusion criteria—tumors positive for pRB	Phase I, phase II	NCT03130439, NCT02806648, NCT03220646, NCT01907607, NCT03355794, NCT02607124, NCT03526250, NCT02555189
Breast	Palbociclib and endocrine therapy	Endpoint measurement—pattern of resistance	Phase II	NCT03184090
Breast	Chemotherapy	Endpoint measurement—correlation with chemotherapy sensitivity	Retrospective	NCT01514565

Note: Clinical trials that include pRB status as either inclusion criteria or an outcome measure.